E
Agile Therapeutics, Inc.
AGRX
OTC PK
E
Sell
6/21/2024Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to E+ from E on 6/21/2024 due to an increase in the volatility index.
Agile Therapeutics, Inc. (AGRX) was upgraded to E+ from E on 6/21/2024 due to an increase in the volatility index.
E
Sell
6/5/2024Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to E from E+ on 6/5/2024 due to a decline in the volatility index and solvency index. Debt to equity increased from -0.13 to -0.04.
Agile Therapeutics, Inc. (AGRX) was downgraded to E from E+ on 6/5/2024 due to a decline in the volatility index and solvency index. Debt to equity increased from -0.13 to -0.04.
E
Sell
5/23/2024Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to E+ from E on 5/23/2024 due to an increase in the volatility index.
Agile Therapeutics, Inc. (AGRX) was upgraded to E+ from E on 5/23/2024 due to an increase in the volatility index.
E
Sell
5/7/2024Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to E from E+ on 5/7/2024 due to a decline in the volatility index.
Agile Therapeutics, Inc. (AGRX) was downgraded to E from E+ on 5/7/2024 due to a decline in the volatility index.
E
Sell
3/28/2024Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to E+ from D on 3/28/2024 due to a significant decline in the valuation index, efficiency index and growth index. Net income declined 459.45% from -$799 to -$4.47M, earnings per share declined from -$0.2708 to -$1.5105, and operating cash flow declined 52.88% from $365 to $172.
Agile Therapeutics, Inc. (AGRX) was downgraded to E+ from D on 3/28/2024 due to a significant decline in the valuation index, efficiency index and growth index. Net income declined 459.45% from -$799 to -$4.47M, earnings per share declined from -$0.2708 to -$1.5105, and operating cash flow declined 52.88% from $365 to $172.
D
Sell
11/17/2023Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D from E+ on 11/17/2023 due to a significant increase in the valuation index, efficiency index and growth index. Operating cash flow increased 104.28% from -$8.52M to $365, earnings per share increased from -$2.1522 to -$0.2708, and net income increased 79.02% from -$3.81M to -$799.
Agile Therapeutics, Inc. (AGRX) was upgraded to D from E+ on 11/17/2023 due to a significant increase in the valuation index, efficiency index and growth index. Operating cash flow increased 104.28% from -$8.52M to $365, earnings per share increased from -$2.1522 to -$0.2708, and net income increased 79.02% from -$3.81M to -$799.
E
Sell
3/14/2023Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to E+ from D on 03/14/2023.
Agile Therapeutics, Inc. (AGRX) was downgraded to E+ from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
Agile Therapeutics, Inc. (AGRX) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to E+ from D on 2/8/2023 due to a decline in the solvency index.
Agile Therapeutics, Inc. (AGRX) was downgraded to E+ from D on 2/8/2023 due to a decline in the solvency index.
D
Sell
8/15/2022Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D from D- on 8/15/2022 due to a noticeable increase in the growth index, solvency index and total return index. Operating cash flow increased 80.11% from -$14.75M to -$2.93M, debt to equity declined from 6.73 to 3.76, and the quick ratio increased from 0.39 to 0.53.
Agile Therapeutics, Inc. (AGRX) was upgraded to D from D- on 8/15/2022 due to a noticeable increase in the growth index, solvency index and total return index. Operating cash flow increased 80.11% from -$14.75M to -$2.93M, debt to equity declined from 6.73 to 3.76, and the quick ratio increased from 0.39 to 0.53.
D
Sell
6/6/2022Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to D- from D on 6/6/2022 due to a decline in the volatility index.
Agile Therapeutics, Inc. (AGRX) was downgraded to D- from D on 6/6/2022 due to a decline in the volatility index.
D
Sell
5/16/2022Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D from D- on 5/16/2022 due to a large increase in the growth index. Earnings per share increased from -$7.9942 to -$3.78, EBIT increased 30.35% from -$22.36M to -$15.57M, and total revenue increased 16.31% from $1.51M to $1.76M.
Agile Therapeutics, Inc. (AGRX) was upgraded to D from D- on 5/16/2022 due to a large increase in the growth index. Earnings per share increased from -$7.9942 to -$3.78, EBIT increased 30.35% from -$22.36M to -$15.57M, and total revenue increased 16.31% from $1.51M to $1.76M.
D
Sell
5/5/2022Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D- from E+ on 05/05/2022.
Agile Therapeutics, Inc. (AGRX) was upgraded to D- from E+ on 05/05/2022.
E
Sell
4/20/2022Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to E+ from D- on 4/20/2022 due to a large decline in the total return index, growth index and volatility index. EBIT declined 41.74% from -$15.77M to -$22.36M, and earnings per share declined from -$0.18 to -$0.1999.
Agile Therapeutics, Inc. (AGRX) was downgraded to E+ from D- on 4/20/2022 due to a large decline in the total return index, growth index and volatility index. EBIT declined 41.74% from -$15.77M to -$22.36M, and earnings per share declined from -$0.18 to -$0.1999.
D
Sell
12/1/2021Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to D- from D on 12/1/2021 due to a decline in the total return index and volatility index.
Agile Therapeutics, Inc. (AGRX) was downgraded to D- from D on 12/1/2021 due to a decline in the total return index and volatility index.
D
Sell
11/9/2021Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D from E+ on 11/09/2021.
Agile Therapeutics, Inc. (AGRX) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to E+ from D on 11/8/2021 due to a significant decline in the total return index, solvency index and volatility index. Debt to equity increased from 0.65 to 1.54, and the quick ratio declined from 2.77 to 1.68.
Agile Therapeutics, Inc. (AGRX) was downgraded to E+ from D on 11/8/2021 due to a significant decline in the total return index, solvency index and volatility index. Debt to equity increased from 0.65 to 1.54, and the quick ratio declined from 2.77 to 1.68.
D
Sell
10/19/2020Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to D from D+ on 10/19/2020 due to a decline in the valuation index and volatility index.
Agile Therapeutics, Inc. (AGRX) was downgraded to D from D+ on 10/19/2020 due to a decline in the valuation index and volatility index.
D
Sell
10/2/2020Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D+ from D on 10/2/2020 due to an increase in the total return index, volatility index and valuation index.
Agile Therapeutics, Inc. (AGRX) was upgraded to D+ from D on 10/2/2020 due to an increase in the total return index, volatility index and valuation index.
D
Sell
9/8/2020Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to D from D+ on 9/8/2020 due to a decline in the valuation index.
Agile Therapeutics, Inc. (AGRX) was downgraded to D from D+ on 9/8/2020 due to a decline in the valuation index.
D
Sell
8/24/2020Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D+ from D on 8/24/2020 due to a major increase in the total return index, valuation index and volatility index.
Agile Therapeutics, Inc. (AGRX) was upgraded to D+ from D on 8/24/2020 due to a major increase in the total return index, valuation index and volatility index.
D
Sell
5/1/2020Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D from D- on 5/1/2020 due to a large increase in the total return index, solvency index and growth index. Debt to equity declined from 0.01 to 0, and operating cash flow increased 35.63% from -$5.08M to -$3.27M.
Agile Therapeutics, Inc. (AGRX) was upgraded to D from D- on 5/1/2020 due to a large increase in the total return index, solvency index and growth index. Debt to equity declined from 0.01 to 0, and operating cash flow increased 35.63% from -$5.08M to -$3.27M.
D
Sell
7/28/2017Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to D- from D on 7/28/2017 due to a decline in the valuation index, solvency index and efficiency index. Total capital declined 15.35% from $50.81M to $43.01M, debt to equity increased from 0.43 to 0.48, and the quick ratio declined from 3.6 to 3.32.
Agile Therapeutics, Inc. (AGRX) was downgraded to D- from D on 7/28/2017 due to a decline in the valuation index, solvency index and efficiency index. Total capital declined 15.35% from $50.81M to $43.01M, debt to equity increased from 0.43 to 0.48, and the quick ratio declined from 3.6 to 3.32.
D
Sell
7/20/2017Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D from D- on 7/20/2017 due to an increase in the valuation index and volatility index.
Agile Therapeutics, Inc. (AGRX) was upgraded to D from D- on 7/20/2017 due to an increase in the valuation index and volatility index.
D
Sell
12/12/2016Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to D- from D on 12/12/2016 due to a decline in the valuation index, efficiency index and solvency index. Debt to equity increased from 0.29 to 0.33, and total capital declined 9.94% from $69.1M to $62.23M.
Agile Therapeutics, Inc. (AGRX) was downgraded to D- from D on 12/12/2016 due to a decline in the valuation index, efficiency index and solvency index. Debt to equity increased from 0.29 to 0.33, and total capital declined 9.94% from $69.1M to $62.23M.
D
Sell
5/10/2016Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D from D- on 5/10/2016 due to an increase in the valuation index, solvency index and efficiency index. The quick ratio increased from 4.34 to 7.79, total capital increased 68.74% from $45.27M to $76.38M, and debt to equity declined from 0.52 to 0.25.
Agile Therapeutics, Inc. (AGRX) was upgraded to D from D- on 5/10/2016 due to an increase in the valuation index, solvency index and efficiency index. The quick ratio increased from 4.34 to 7.79, total capital increased 68.74% from $45.27M to $76.38M, and debt to equity declined from 0.52 to 0.25.
D
Sell
3/11/2016Downgrade
Agile Therapeutics, Inc. (AGRX) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and efficiency index. Total capital declined 5.96% from $48.14M to $45.27M.
Agile Therapeutics, Inc. (AGRX) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and efficiency index. Total capital declined 5.96% from $48.14M to $45.27M.
D
Sell
6/1/2015Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D from D- on 6/1/2015 due to a major increase in the volatility index, total return index and solvency index. The quick ratio increased from 4.47 to 11.19, and debt to equity declined from 0.41 to 0.31.
Agile Therapeutics, Inc. (AGRX) was upgraded to D from D- on 6/1/2015 due to a major increase in the volatility index, total return index and solvency index. The quick ratio increased from 4.47 to 11.19, and debt to equity declined from 0.41 to 0.31.
D
Sell
2/2/2015Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to D- from E+ on 2/2/2015 due to an increase in the growth index and volatility index. Operating cash flow increased 262.79% from -$2.14M to -$7.78M, and EBIT increased 73.09% from -$3.49M to -$6.05M.
Agile Therapeutics, Inc. (AGRX) was upgraded to D- from E+ on 2/2/2015 due to an increase in the growth index and volatility index. Operating cash flow increased 262.79% from -$2.14M to -$7.78M, and EBIT increased 73.09% from -$3.49M to -$6.05M.
E
Sell
11/3/2014Upgraded
Agile Therapeutics, Inc. (AGRX) was upgraded to E+ from E on 11/3/2014 due to a substantial increase in the total return index and valuation index.
Agile Therapeutics, Inc. (AGRX) was upgraded to E+ from E on 11/3/2014 due to a substantial increase in the total return index and valuation index.
E
Sell
8/22/2014None
Agile Therapeutics, Inc. (AGRX) was downgraded to E from U on 08/22/2014.
Agile Therapeutics, Inc. (AGRX) was downgraded to E from U on 08/22/2014.
